Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.  The company is also developing NCX 4251, a proprietary formulation of fluticasone, for dry eye disease.  Nicox generates revenue from VYZULTA® in glaucoma and ZERVIATE® in allergic conjunctivitis, both of which are commercialized by partners.

Visit sponsor site

To view all of our sponsors, please click here